Last reviewed · How we verify

Camrelizumab plus Apatinib

Wan-Guang Zhang · Phase 2 active Small molecule

Camrelizumab is a PD-1 inhibitor, and Apatinib is a VEGFR-2 tyrosine kinase inhibitor.

Camrelizumab is a PD-1 inhibitor, and Apatinib is a VEGFR-2 tyrosine kinase inhibitor. Used for Advanced gastric cancer, Non-small cell lung cancer.

At a glance

Generic nameCamrelizumab plus Apatinib
SponsorWan-Guang Zhang
Drug classPD-1 inhibitor and VEGFR-2 tyrosine kinase inhibitor
TargetPD-1 and VEGFR-2
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Camrelizumab works by binding to PD-1 and blocking its interaction with PD-L1, thereby enhancing T-cell activation and proliferation. Apatinib, on the other hand, inhibits VEGFR-2, which is involved in angiogenesis and tumor growth.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: